Prevention and reversal of LV remodeling with neurohormonal inhibitors

Current Treatment Options in Cardiovascular Medicine

Volumn 6, Issue 4, 2004, Pages 313-325

  Patten, Richard D ^a   Soman, Prem ^b  

^a Molecular Cardiology Research Institute   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALTEPLASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LITHIUM; LOSARTAN; METOPROLOL; METOPROLOL TARTRATE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NEUROHORMONE; NONSTEROID ANTIINFLAMMATORY AGENT; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; STREPTOKINASE; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

ABDOMINAL CRAMP; ACUTE HEART INFARCTION; ADRENERGIC RECEPTOR BLOCKING; ADRENERGIC SYSTEM; AGRANULOCYTOSIS; ANGIONEUROTIC EDEMA; BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED DRUG RELEASE; CORRELATION COEFFICIENT; COST EFFECTIVENESS ANALYSIS; COUGHING; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG ANTAGONISM; DRUG COST; DRUG CROSS REACTIVITY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FLU LIKE SYNDROME; GASTRITIS; GYNECOMASTIA; HEADACHE; HEART DEATH; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE INJURY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HUMAN; HYPERKALEMIA; HYPERTRIGLYCERIDEMIA; IMPOTENCE; INCIDENCE; KIDNEY DYSFUNCTION; LETHARGY; LIVER DYSFUNCTION; MENSTRUATION DISORDER; NAUSEA AND VOMITING; NIGHTMARE; NONHUMAN; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; PANCREATITIS; PATHOPHYSIOLOGY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPTOMATOLOGY; SYNCOPE; TASTE DISORDER; URTICARIA;

EID: 4344712834     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-004-0033-4     Document Type: Review

References (91)

1. Chareonthaitawee P, Christian TF, Hirose K, et al.: Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction. J Am Coll Cardiol 1995, 25:567-573.
2. van Gilst WH, Kingma JH, Peels KH, et al.: Which patients benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the captopril and thrombolysis study (CATS). J Am Coll Cardiol 1996, 28:114-121.
3. Schulman SP, Weiss JL, Becker LC, et al.: Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarction. Am J Cardiol 1995, 76:764-770.
4. Erlebacher JA, Weiss JL, Eaton LW, et al.: Late effects of acute infarct dilation on heart size: a two dimensional echocardiographic study. Am J Cardiol 1982, 49:1120-1126.
5. McKay RG, Pfeffer MA, Pasternak RC, et al.: Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 1986, 74:693-702.
6. Rumberger JA, Behrenbeck T, Breen JR, et al.: Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans. J Am Coll Cardiol 1993, 21:673-682.
7. Jeremy RW, Allman KC, Bautovitch G, Harris PJ: Patterns of left ventricular dilation during the six months after myocardial infarction. J Am Coll Cardiol 1989, 13:304-310.
8. Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA: Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. Am Coll Cardiol 1992, 19:1136-1144.
9. Patten RD, Udelson JE, Konstam MA: Ventricular remodeling and its prevention in the treatment of heart failure. Curr Opin Cardiol 1998, 13:162-167.
10. Pfeffer MA, Pfeffer JM: Ventricular enlargement and reduced survival after myocardial infarction. Circulation 1987, 75:IV93-IV97.
11. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction, experimental observations and clinical implications. Circulation 1990, 81:1161-1172.
12. White HD, Norris RM, Brown MA, et al.: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987, 76:44-51.
13. Hammermeister KE, DeRouen TA, Dodge HT: Variables predictive of survival in patients with coronary artery disease: Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic and quantitative angiographic evaluations. Circulation 1979, 59:421-430.
14. Migrino RQ, Young JB, Ellis SG, et al.: End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. Circulation 1997, 96: 116-121.
15. Bolognese L, Neskovic AN, Parodi G, et al.: Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002, 106:2351-2357.
16. Gaudron P, Kugler I, Hu K, et al.: Time course of cardiac structural, functional and electrical changes in asymptomatic patients after myocardial infarction: their interrelation and prognostic impact. J Am Coll Cardiol 2001, 38:33-40.
17. St. John Sutton M, Lee D, Rouleau JL, et al.: Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation 2003, 107:2577-2582.
18. Konstam MA, Rousseau MF, Kronenberg MW, et al.: Effects of the angiotensin converting enzyme inhibitor, enalapril, on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992, 86:431-438.
19. Konstam MA, Kronenberg MW, Rousseau MF, et al.: Effects of the angiotensin converting enzyme inhibitor, enalapril, on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993, 88:2277-2283.
20. Doughty M, Robert N, Whalley B, et al.: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997, 29:1060-1066.
21. Rousseau MF, Konstam MA, Benedict CR, et al.: Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994, 73:488-493.
22. Tamura T, Onodera T, Said S, Gerdes AM: Correlation of myocyte lengthening to chamber dilation in the spontaneously hypertensive heart failure (SHHF) rat. J Mol Cell Cardiol 1998, 30:2175-2181.
23. Beltrami CA, Finato N, Rocco M, et al.: The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol 1995, 27:291-305.
24. Narula J, Kolodgie FD, Virmani R: Apoptosis and cardiomyopathy. Curr Opin Cardiol 2000, 15:183-188.
25. Sam F, Sawyer DB, Chang DL, et al.: Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart. Am J Physiol Heart Circ Physiol 2000, 279:H422-H428.
26. Baldi A, Abbate A, Bussani R, et al.: Apoptosis and post-infarction left ventricular remodeling. J Mol Cell Cardiol 2002, 34:165-174.
27. Abbate A, Biondi-Zoccai GGL, Bussani R, et al.: Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J Am Coll Cardiol 2003, 41:753-760.
28. Mani K, Kitsis RN: Myocyte apoptosis: programming ventricular remodeling. J Am Coll Cardiol 2003, 41:761-764.
29. Brilla CG, Reans GP, Maisch B, Weber KT: Renin-angiotensin system and myocardial fibrosis in hypertension: regulation of the myocardial collagen matrix. Eur Heart J 1993, 14:57-61.
30. Weber KT, Janicki JS, Shroff SG, et al.: Collagen remodeling of the pressure overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988, 62:757-765.
31. Weber KT: Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989, 13:1637-1652.
32. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and the renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
33. Hirsch AT, Talsness CE, Schunkert H, et al.: Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991, 69:475-482.
34. Sadoshima J, Xu Y, Slayter HS, Izumo S: Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes. Cell 1993, 75:977-984.
35. Sadoshima J, Izumo S: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res 1993, 73:413-423.
36. Schunkert H, Sadoshima JI, Cornelius T, et al.: Angiotensin II-induced growth responses in isolated adult rat hearts: evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res 1995, 76:489-497.
37. Pfeffer MA, Pfeffer JM, Braunwald E: Myocardial infarct size and ventricular function in rats. Circ Res 1979, 44:503-512.
38. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P: Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985, 72:406-412.
39. Pfeffer JM, Pfeffer MA, Braunwald E: Influence of chronic captopril on the infarcted left ventricle of the rat. Circ Res 1985, 57:84-95.
40. Patten RD, Aronovitz MJ, Einstein M, et al.: Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse. Clin Sci (Lond) 2003, 104:109-118.
41. Taylor K, Patten RD, Smith JJ, et al.: Divergent Effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. J Cardiovasc Pharmacol 1998, 31:654-660.
42. Michel JB, Lattio AL, Salzmann JL, et al.: Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction. Circ Res 1988, 62:641-650.
43. McDonald KM, Garr MD, Carlyle PF, et al.: Relative effects of a1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. CIrculation 1994, 90:3034-3046.
44. Mulrow PJ: Angiotensin II and aldosterone regulation. Regul Pept 1999, 80:27-32.
45. Lombes M, Oblin ME, Gasc JM, et al.: Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992, 71:503-510.
46. Mizuno Y, Yoshimura M, Yasue H, et al.: Aldosterone production is activated in failing ventricle in humans. Circulation 2001, 103:72-77.
47. Yamamoto N, Yasue H, Mizuno Y, et al.: Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 2002, 39:958-962.
48. Brilla CG, Zhou G, Matsubara L, Weber KT: Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994, 26:809-820.
49. Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994, 93:2578-2583.
50. Silvestre JS, Heymes C, Oubenaissa A, et al.: Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999, 99:2694-2701.
51. Delyani JA, Robinson EL, Rudolph AE: Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001, 281:H647-H654.
52. Suzuki G, Morita H, Mishima T, et al.: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002, 106:2967-2972.
53. Eriksson SV, Eneroth P, Kjekshus J, et al.: Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Clin Cardiol 1994, 17:603-606.
54. Benedict CR, Johnstone DE, Weiner DH, et al.: Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994, 23:1410-1420.
55. Francis GS, Benedict C, Johnstone DE, et al.: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82:1724-1729.
56. Yamazaki T, Komuro I, Zou Y, et al.: Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1- and beta-adrenoceptors. Circulation 1997, 95:1260-1268.
57. Tomita H, Nazmy M, Kajimoto K, et al.: Inducible cAMP early repressor (ICER). Is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to beta-adrenergic receptor stimulation? Circ Res 2003, 93:12-22.
58. Dorn GW 2nd: Adrenergic pathways and left ventricular remodeling. J Card Fail 2002, 8:S370-S373.
59. Grimm D, Elsner D, Schunkert H, et al.: Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. Cardiovasc Res 1998, 37:91-100.
60. McDonald KM, Rector T, Carlyle PF, et al.: Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol 1994, 24:1762-1768.
61. Morita H, Suzuki G, Mishima T, et al.: Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Cardiovasc Drugs Ther 2002, 16:443-449.
62. Sabbah HN, Sharov VG, Gupta RC, et al.: Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J Am Coll Cardiol 2000, 36:1698-1705.
63. Pfeffer MA, Lamas GA, Vaughan DE, et al.: Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988, 319:80-86.
64. Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992, 327:669-677.
65. St. John Sutton M, Pfeffer MA, Plappert T, et al.: Quantitative two dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction, the protective effect of captopril. Circulation 1994, 89:68-75.
66. Effects of lisinopril and transdermal glyseryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. GISSI-3 [no authors listed]. Lancet 1994, 343:1115-1122.
67. Nicolosi GL, Latini R, Marino P, et al.: The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 trial. Eur Heart J 1996, 17:1646-1656.
68. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 [no authors listed]. Lancet 1995, 345:669-685.
69. Effect of angiotensin converting enzyme inhibition with enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure: results of the treatment trial of the Studies of Left Ventricular Dysfunction (SOLVD); a randomized double blind trial. The SOLVD Investigators [no authors listed]. N Engl J Med 1991, 325:293-302.
70. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD [no authors listed]. N Engl J Med 1992, 327:685-691.
71. Greenberg B, Quinones MA, Koilpillai C, et al.: Effects of Long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: Results of the SOLVD echocardiography substudy. Circulation 1995, 91:2573-2581.
72. Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. New Engl J Med 1996, 334:1349-1355.
73. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385-1390.
74. Packer M, Fowler MB, Roecker EB, et al.: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 2002, 106:2194-2199.
75. Hjalmarson A, Goldstein S, Fagerberg B, et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000, 283:1295-1302.
76. Basu S, Senior R, Raval U, et al.: Beneficial effects of intravenous and oral carvedilol in acute myocardial infarction: a placebo controlled, randomized trial. Circulation 1997, 96:183-191.
77. Doughty RN, Whalley GA, Walsh HA, et al.: Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: The CAPRICORN echo substudy. Circulation 2004, 109:201-206.
78. Groenning BA, Nilsson JC, Sondergaard L, et al.: Anti-remodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000, 36:2072-2080.
79. Packer M, Antonopoulos GV, Berlin JA, et al.: Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001, 141:899-907.
80. Poole-Wilson PA, Swedberg K, Cleland JGF, et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7-13.
81. Pitt B, Segal R, Martinez FA, et al.: Randomized trial of losartan versus captopril in patents over 65 with heart failure. Evaluation of Losartan in the Elderly Study (ELITE). Lancet 1997, 349:747-752.
82. Konstam MA, Patten RD, Thomas I, et al.: Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J 2000, 139:1081-1087.
83. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582-1587.
84. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
85. Wong M, Staszewsky L, Latini R, et al.: Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002, 40:970-975.
86. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
87. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
88. Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000, 102:2700-2706.
89. Hayashi M, Tsutamoto T, Wada A, et al.: Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003, 107:2559-2565.
90. Kasama S, Toyama T, Kumakura H, et al.: Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003, 41:574-581.
91. Tsutamoto T, Wada A, Maeda K, et al.: Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001, 37:1228-1233.